Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01499303 · ClinicalTrials.gov registry record · Phase 2

Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer

A Phase 2 study of Diffuse Large B Cell Lymphoma, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
101
Enrollment target
20
Study locations

NCT01499303 is a Phase 2 study of Diffuse Large B Cell Lymphoma that has completed, run by AstraZeneca. The registered enrollment target is 101 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 18 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01499303, a Phase 2 study of Diffuse Large B Cell Lymphoma, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
101 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the effectiveness of fostamatinib (200 mg twice a day) in patients with worsening or unmanageable lymphoma with a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (abbreviated as DLBCL)

Conditions Studied

Diffuse Large B Cell Lymphoma

Interventions

  • DRUG Fostamatinib

Study Locations (20)

New York

  • Research Site - New York
  • Research Site - Rochester

Texas

  • Research Site - Houston
  • Research Site - San Antonio

Alabama

  • Research Site - Huntsville

Colorado

  • Research Site - Denver

Connecticut

  • Research Site - New Haven

Florida

  • Research Site - Sarasota

Georgia

  • Research Site - Atlanta

Iowa

  • Research Site - Iowa City

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2011-12
Est. Completion 2013-10
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01499303

The ClinicalTrials.gov registry entry for NCT01499303 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (54% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Fostamatinib is the first listed.

NCT01499303 reports 20 study locations spanning 18 distinct geographic areas - top geographies include New York, Texas, Alabama.

Frequently Asked Questions

What is clinical trial NCT01499303 about?

NCT01499303 is a clinical study titled "Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer". This study will evaluate the effectiveness of fostamatinib (200 mg twice a day) in patients with worsening or unmanageable lymphoma with a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (abbreviated as DLBCL)

What is the current status of trial NCT01499303?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2011-12. Estimated completion is 2013-10.

What conditions does trial NCT01499303 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.

What interventions are being tested in trial NCT01499303?

The interventions under investigation include: Fostamatinib (DRUG).

Who is sponsoring clinical trial NCT01499303?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01499303 being conducted?

This trial has 20 study locations across Alabama, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Large B Cell Lymphoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.